Company:  AEGLEA BIOTHERAPEUTICS, I ... (AGLE)
Form Type:  DEF 14A
Filing Date:  4/21/2017 
CIK:  0001636282 
Address:  901 S. MOPAC EXPRESSWAY, STE. 250
BARTON OAKS PLAZA ONE
 
City, State, Zip:  AUSTIN, Texas 78746 
Telephone:  (512) 942-2935 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$7.87  
Change: 
-0.015 (-0.19%)  
Trade Time: 
01:49 PM EST  
Market Cap: 
$166.50M
Trade AGLE now with 

© 2018  
Description of Business
We are a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. We believe our novel approach of utilizing human enzymes offers advantages over bacterial enzyme-based approaches including a more favorable safety profile that may provide a greater likelihood of clinical success. Our capabilities in enzyme engineering, preclinical disease modelling, and drug development in both rare genetic disease and cancer allow us to identify and advance innovative opportunities to address important unmet medical needs for the benefit of patients.
Register and access this filing in:     
  FORM DEF 14A
    NOTICE OF ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON JUNE ...
    PROXY STATEMENT FOR 2017 ANNUAL MEETING OF STOCKHOLDERS
    Compensation Committee Interlocks and Insider Participation
    PROPOSAL NO. 1
      NAME AND TITLE
      NAME AND TITLE
      COMPENSATION TABLE
    Non-Employee Director Compensation Arrangements
    PROPOSAL NO. 2
    PROPOSAL NO. 3
    SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
      BENEFICIAL OWNERS
      NAME AND TITLE
    EXECUTIVE COMPENSATION
      OPTIONS AGGREGATE
    REPORT OF THE AUDIT COMMITTEE
    Stockholder Proposals to be Presented at Next Annual Meeting
    OTHER MATTERS
    THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. KEEP ...